Sarepta Therapeutics Inc.

In News

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits

Stocktwits - Jul 17, 2026

The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies - Yahoo Finance

Yahoo Finance - Jul 14, 2026

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments - Sarepta Therapeutics

Sarepta Therapeutics - May 06, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) - GlobeNewswire

GlobeNewswire - Jul 13, 2026

Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

GuruFocus - Jul 14, 2026

Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape - DirectorsTalk Interviews

DirectorsTalk Interviews - Jul 13, 2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Business Wire - Jun 30, 2026

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments - Sarepta Therapeutics

Sarepta Therapeutics - Feb 25, 2026

Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy - Yahoo Finance

Yahoo Finance - Jun 05, 2026

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits

Stocktwits - Jul 13, 2026

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics

Sarepta Therapeutics - Mar 25, 2026

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits

Stocktwits - Jul 16, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment